In May, U.S.-based Abbott Labs secured the top spot in India’s growing pharmaceutical industry with its US$ billion takeover of Piramal. In , Ajay Piramal promoted Piramal Healthcare sold off its main formulation business to Abbott India for over INR 17, crore and announced a buy-back of . When US-based global health care major Abbott acquired the formulations business of Piramal Healthcare in a $billion deal in , it had.
|Published (Last):||7 June 2015|
|PDF File Size:||16.50 Mb|
|ePub File Size:||13.56 Mb|
|Price:||Free* [*Free Regsitration Required]|
Piramal Abbott Story : Deal Impact | Healthcare | Enterprises | M&A Critique
It makes a lot of sense if they can pull off all the integration issues. Disagreements over valuation have prevented more deals from getting done. Piramla created this value for the company, a part of it was distributed to the shareholders by the way of buyback of shares. The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry and invest in the remaining business.
Abbott to pay $3.7 billion for unit of India’s Piramal
The Accidental Caviar King. Now, Piramal on its own has that opportunity.
Business RBI to release new Rs. But new Wharton research provides better insight into the benefits of PE buyouts. These other players are not even interested in doing that. It exited the investment in April with a 52 percent gain. He finds himself in an enviable position of sitting on capital at a time when the economy is going through some stress. Since then, further pharmaceutical deals have been expected, as global majors search for growth and low-cost production of generics, as patents on major branded drugs are set to expire.
Ajay Piramal, however, reiterated that he was not exiting the business. Sensex finishes year above 36, posts third straight annual gain. The Abbott-Piramal combine reports to him, but he notes it will be run as a standalone business unit after the merger takes effect later this year.
It is not so much a concern about the downside, but about how we maximize the opportunity.
Seven years after Piramal deal, Abbott way off revenue target
Its other businesses include third-party manufacturing and pathology laboratories. Expecting the unexpected Oil’s still not well Sanjiv Mehta: Obviously, whoever wants to strengthen Indian presence through buyouts, will have to shell pjramal much more due to the higher demand for Indian assets.
Evergrande Group’s Sea Venice real estate project has attracted hordes of buyers in China’s leisure property market. But that is also changing, she says. Chaudhuri acknowledges those new realities, but with a patriotic tinge.
It is paying roughly 8. More than one voice suggested the company return a part of the cash to its shareholders. Read Post a comment. He also acknowledged that the company had become a conglomerate and the structure made Piramal Enterprises difficult to understand. Only fill in if you are not human. After studying law I vectored towards journalism by accident and it’s the only job I’ve done since.
Related Videos ET Now: Video Slideshow Audio Twinterview. Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities. Unilever’s Bargain Offer Economic Milestone: According to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions.
A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma? – [email protected]
All Comments Your Activity. The year of the last action hero.
Abbott will add branded generic drugs from the Piramal portfolio, including Phensedyl, one of the top two pharma brands in the country. This deal valued Diagnostic services business at 3x FY Sales.
InPiramal Enterprises Ltd.
It takes a time to yield a return in real estate business. It has all the makings of a billion dollar enterprise for Piramal Enterprises. Shares in Mumbai-based Piramal closed In addition, a tie-up with the Canadian Pension Plan has seen it invest their money in residential real estate in India.
But the deal takes them to the number one slot, he adds.
The 10 big questions for – Part 2. Ajay Piramal has also taken over as chairman of Shriram Capital. The Abbott-Piramal deal is the latest in a wave of consolidation within the global pharmaceutical industry over the past few years. It’s a job that has taken me on a private jet to Jaisalmer – where I wrote India’s first feature on fractional ownership of business jets – to the badlands of west UP where India’s sugar economy is inextricably now tied to politics.